Cell and Gene Therapy Market Size Share Trends and Industry Forecast 2034
Cell and Gene Therapy Market Size Share Trends and Industry Forecast 2034
The Cell and gene therapy market growth in 2026 represents a revolutionary approach in modern medicine, focusing on modifying or replacing defective genes and cells to treat diseases at their root cause. These therapies are gaining momentum due to their potential to provide long-term or even permanent treatment outcomes, particularly in oncology, rare genetic disorders, and autoimmune diseases. The increasing number of clinical trials and regulatory approvals is further accelerating market growth globally.
According to Fortune Business Insights, the global Cell and Gene Therapy Market size was valued at USD 12.21 billion in 2025 and is projected to grow from USD 16.45 billion in 2026 to USD 143.55 billion by 2034, exhibiting a CAGR of 31.10% during the forecast period. The rapid expansion of this market reflects the increasing adoption of advanced therapies designed to treat, prevent, and potentially cure complex genetic and chronic diseases. North America dominated the cell and gene therapy market with a market share of 52.58% in 2025, driven by strong research infrastructure, favorable regulatory frameworks, and high investments in biotechnology innovation.
Vertex Pharmaceuticals Incorporated (U.S.)
Novartis AG (Switzerland)
Bristol-Myers Squibb Company (U.S.)
Krystal Biotech, Inc. (U.S.)
Rocket Pharmaceuticals (U.S.)
Hoffmann-La Roche Ltd. (Switzerland)
Bayer AG (Germany)
CRISPR Therapeutics (Switzerland)
Gilead Sciences, Inc. (U.S.)
Adaptimmune (U.K.)
The growing prevalence of chronic and genetic diseases is one of the primary drivers of the cell and gene therapy market. The rising demand for personalized medicine and targeted therapies has significantly boosted research and development activities in this field. Additionally, advancements in gene-editing technologies, such as CRISPR, and increasing investments from both public and private sectors are fueling innovation.
Another major growth factor is the increasing number of successful clinical trials and product approvals, which are encouraging healthcare providers to adopt these therapies. Furthermore, strong support from regulatory authorities for accelerated approval pathways has enhanced market penetration.
However, the market faces certain restraints, including the high cost of therapy development and treatment, which limits accessibility for many patients. Manufacturing complexities, stringent regulatory requirements, and challenges in large-scale production also act as barriers to growth. Despite these challenges, continuous technological advancements are expected to mitigate these issues over time.
The cell and gene therapy market report provides comprehensive insights into market size, share, growth trends, and future forecasts. It covers detailed analysis of key market segments, competitive landscape, and regional performance. The report highlights emerging opportunities, technological advancements, and strategic initiatives adopted by leading players. It also includes in-depth information about clinical developments, regulatory scenarios, and investment trends shaping the market.
The competitive landscape of the cell and gene therapy market is characterized by intense innovation and strategic collaborations. Leading companies are focusing on expanding their product pipelines, investing in research and development, and forming partnerships to enhance their market presence. Mergers and acquisitions are also common strategies used to strengthen capabilities and accelerate product commercialization.
Key players are increasingly investing in advanced manufacturing technologies and expanding their production capacities to meet the growing demand. Additionally, collaborations between pharmaceutical companies and research institutions are playing a crucial role in accelerating the development of novel therapies.
The cell and gene therapy market is segmented based on
By Type (By Cell Therapy {By Therapy Type [CAR-T Cell Therapy, TCR-T Cell Therapy, Natural Killer Cells, &Others]
By Product (Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti, & Others]
By Indication [Oncology & Others]}, and
By Gene Therapy {By Vector Type [Viral Vectors & Non-Viral Vectors]
By Product Type [Zolgensma, Luxturna, Roctavian, & Others],
and By Indication [Genetic Diseases, Ophthalmology, Hematology, & Others]})
By End User (Hospitals & Clinics, Specialty Clinics, & Others)
Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/cell-and-gene-therapy-market-114130
North America holds the largest share of the global cell and gene therapy market, accounting for 52.58% in 2025. The region’s dominance is attributed to the presence of leading biotechnology companies, strong research infrastructure, and favorable reimbursement policies. The United States, in particular, is a major contributor due to its robust clinical trial ecosystem and high healthcare expenditure.
Europe is another significant market, supported by increasing government initiatives and investments in advanced therapies. The region is witnessing steady growth due to the rising adoption of innovative treatment approaches and the presence of established pharmaceutical companies.
Asia Pacific is expected to experience rapid growth during the forecast period, driven by improving healthcare infrastructure, increasing awareness about advanced therapies, and growing investments in biotechnology research. Emerging economies in this region are focusing on enhancing their capabilities in cell and gene therapy development.
The future of the cell and gene therapy market looks highly promising, with significant advancements expected in technology and treatment methodologies. The increasing focus on personalized medicine and precision healthcare is likely to drive demand for these therapies. Innovations in gene-editing tools and cell engineering techniques will further enhance treatment efficacy and safety.
Additionally, ongoing research and development activities are expected to expand the application scope of cell and gene therapies beyond oncology and rare diseases. The integration of artificial intelligence and data analytics in therapy development is also anticipated to accelerate innovation and improve clinical outcomes.
As the market continues to evolve, strategic collaborations, increased funding, and supportive regulatory frameworks will play a crucial role in shaping its growth trajectory. The rising adoption of these therapies is expected to transform the healthcare landscape, offering new hope for patients with previously untreatable conditions.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com